Regresar

Guzik T.J.

440

Coauthors

Documentos

Volumen de publicaciones por año

Cargando gráfico

Año de publicación	Num. Publicaciones
2017	2
2018	1
2019	2
2021	2
2022	1

Publicaciones por áreas de conocimiento

Cargando gráfico

Área de conocimiento	Num. Publicaciones
Enfermedad cardiovascular	6
Medicina interna	3
Farmacología	1

Publicaciones por áreas temáticas

Cargando gráfico

Área temática	Num. Publicaciones
Enfermedades	8
Farmacología y terapéutica	7
Medicina y salud	3
Cirugía y especialidades médicas afines	2
Fisiología humana	1

Principales fuentes de datos

Origen	Num. Publicaciones
Scopus	8
Google Scholar	6
RRAAE	0

Cargando gráfico

Coautores destacados por número de publicaciones

Coautor	Num. Publicaciones
Yusuf S.	8
Bhatt D.L.	8
Eikelboom J.W.	8
Fox K.A.A.	8
Dagenais G.R.	7
Branch K.R.H.	7
Anand S.S.	7
Avezum A.J.	7
Connolly S.J.	7
Maggioni A.P.	7

Cargando gráfico

Top Keywords

Cargando gráfico

Publicaciones del autor

Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial

Article

Abstract: Background: Direct oral anticoagulants are administered in fixed doses irrespective of body weight,

Palabras claves:

Cardiovascular Risk, DOAC, prevention, rivaroxaban

Autores:

Berkowitz S.D., Bhatt D.L., Dyal L., Eikelboom J.W., Fox K.A.A., Guzik T.J., Muehlhofer E., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Ramasundarahettige C., Yusuf S.

Fuentes:

google

scopus

Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease

Article

Abstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared

Palabras claves:

aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxaban

Autores:

Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.

Fuentes:

google

scopus

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

Article

Abstract: Background & Aims: Antiplatelets and anticoagulants are associated with increased upper gastrointest

Palabras claves:

drug, Heart Disease Prevention, Stomach, Thrombosis

Autores:

Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Commerford P.J., Connolly S.J., Cook-Bruns N., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.

Fuentes:

google

scopus

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Article

Abstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. T

Palabras claves:

bacteria, CVD, Reflux, Thrombosis

Autores:

Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.

Fuentes:

google

scopus

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

Article

Abstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral

Palabras claves:

aspirin, Coronary artery disease, Peripheral artery disease, rivaroxaban

Autores:

Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.

Fuentes:

scopus